Literature DB >> 8133400

Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1.

T Rajkumar1, C S Gooden, N R Lemoine, W J Gullick, C S Goden.   

Abstract

We have examined the expression of the c-erbB-3 protein in a wide range of tumours of the gastrointestinal (GI) tract using immunocytochemical staining. Two antibodies were employed, a polyclonal antibody, 49.3, and a new monoclonal antibody, RTJ1, both raised to a synthetic peptide from the cytoplasmic domain of the human c-erbB-3 protein. The antibodies recognize c-erbB-3 by immunoprecipitation and Western blotting of lysate prepared from a cell line engineered to overexpress the protein. Both antibodies also detect expression of the protein in formalin-fixed, paraffin-embedded human tissues. The RTJ1 monoclonal antibody gave superior staining, showing lower background and more pronounced cell surface immunoreactivity. The c-erbB-3 protein was found in normal epithelial cells throughout the GI tract, in squamous epithelium of the oropharanyx and oesophagus, in the parietal cells of the stomach, and in the surface enterocytes of the small and large bowel. Seventy-six tumours arising at these sites were examined for c-erbB-3 protein expression. Widely varying levels of expression were seen, from absent to intense staining with cell membrane accentuation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8133400     DOI: 10.1002/path.1711700309

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  18 in total

1.  Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.

Authors:  Chunrong Li; Toni M Brand; Mari Iida; Shyhmin Huang; Eric A Armstrong; Albert van der Kogel; Deric L Wheeler
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

2.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Identification of ErbB3-stimulated genes using modified representational difference analysis.

Authors:  C F Edman; S A Prigent; A Schipper; J R Feramisco
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

Review 4.  The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Authors:  Dhara N Amin; Marcia R Campbell; Mark M Moasser
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

Review 5.  The type I growth factor receptors in human breast cancer.

Authors:  T Rajkumar; W J Gullick
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

6.  c-erbB3 protein expression in ovarian cancer.

Authors:  T Rajkumar; G W Stamp; C M Hughes; W J Gullick
Journal:  Clin Mol Pathol       Date:  1996-08

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats.

Authors:  Eleftherios Vairaktaris; Lambros Goutzanis; Stavros Vassiliou; Sofia Spyridonidou; Emeka Nkenke; Georgios Papageorgiou; Pashalis Strantzias; Andreas Lazaris; Christos Yapijakis; Efstratios Patsouris
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-18       Impact factor: 4.553

9.  Differential distribution of human epidermal growth factor receptor family in acute pancreatitis.

Authors:  M Ebert; H Friess; M W Büchler; M Korc
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

Review 10.  The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

Authors:  Luigi Aurisicchio; Emanuele Marra; Giuseppe Roscilli; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.